Drugs / Retosiban
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT02377414 | Mar → Apr 2015 | pregnancy disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01867996 | Jun → Sep 2013 | pregnancy disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01702376 | Oct 2012 → Jan 2013 | pregnancy disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01627587 | Dec 2011 → Feb 2012 | obstetric disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00449709 | Mar 2007 → ? | pregnancy disorder, premature ejaculation | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT00457925 | Oct 2006 → ? | obstetric disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00404768 | Oct 2007 → Jul 2011 | obstetric disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT02377466 | Feb 2016 → Jul 2017 | pregnancy disorder | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 3 | NCT02292784 | Jun 2015 → Sep 2019 | pregnancy disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02292771 | Mar 2015 → Aug 2017 | pregnancy disorder | GlaxoSmithKline | Terminated | Missed primary Stop: Enrollment |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-03-17 | GlaxoSmithKline | GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour gsk.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Retosiban | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01867996 ↗ |
| Known as | GSK221149 | “A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)” NCT01867996 ↗ |
| Known as | GSK221149A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00457925 ↗ |
| Action | Inhibit | “block the effects of oxytocin” NCT00404768 ↗1“Oxytocin receptor antagonist” CHEMBL429736 ↗ |
| Modality | Small molecule | “Retosiban is a small molecule oxytocin receptor antagonist” PMID 26138866 ↗ Jun 2015 |
| Route | Intravenous | “given an intravenous infusion of GSK221149A” NCT00404768 ↗ |
| Target | OXTR | “Oxytocin receptor antagonist” CHEMBL429736 ↗ |